Wiliam Mark

The Post-Cardiac Arrest Syndrome market report provides current treatment practices, emerging drugs, Post-Cardiac Arrest Syndrome market share of the individual therapies, current and forecasted Post-Cardiac Arrest Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Post-Cardiac Arrest Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Post-Cardiac Arrest Syndrome market. Post-Cardiac Arrest Syndrome Overview A clinical condition known as post-cardiac arrest syndrome includes widespread brain damage, myocardial failure, macrocirculatory dysfunction, increased susceptibility to infection, and chronic triggering disease (ie, the cause of the arrest). The severity of the results varies and is influenced by the precipitating events, the patient's health prior to cardiac arrest, the amount of time it takes

  ASCO 2022: SKYSCRAPER-02 fails The primary results of phase III SKYSCRAPER-02 trial reveals that atezolizumab + carboplatin + etoposide with or without tiragolumab fails to show significant results in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). Etoposide Mechanism of Action :  Type II DNA topoisomerase inhibitors Atezolizumab Mechanism of Action :  Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors Tiragolumab (anti-TIGIT) is a novel immune checkpoint inhibitor that is present in many cancers. TIGIT expression is highly correlated with PD-L1 expression, and tiragolumab is a human anti-TIGIT monoclonal antibody that may synergize with other immunotherapies. With a median follow-up of 14.3 months, the median PFS in the primary analysis set, which excluded patients without brain metastases, was 5.4 months. The median PFS in the placebo group was 5.6 months. The interim OS in the primary analysis set was 13.6 months in both groups

  DelveInsight's " Phosphoglucomutase 1 Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Phosphoglucomutase 1 Deficiency, historical and forecasted epidemiology as well as the Phosphoglucomutase 1 Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Phosphoglucomutase 1 Deficiency market report provides current treatment practices, emerging drugs, Phosphoglucomutase 1 Deficiency market share of the individual therapies, current and forecasted Phosphoglucomutase 1 Deficiency market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Phosphoglucomutase 1 Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Phosphoglucomutase 1 Deficiency market. Do you want to know its market sh

  Soft Tissue Sarcoma with lung metastases Market DelveInsight's Soft Tissue Sarcoma (STS) with lung metastases Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Soft Tissue Sarcoma (STS) with lung metastases, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma (STS) with lung metastases market trends in 7MM. Spondylolisthesis Market DelveInsight's Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Spondylolisthesis, historical and forecasted epidemiology as well as the Spondylolisthesis market trends in 7MM. Shigella Infections Market DelveInsight's Shigella Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Shigella Infections forecasted epidemiology Sarcopenia Market DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forec

  LAG-3 combination drug Opdualag: ASCO 2022 Bristol Myers Squibb presented a subgroup analysis from the RELATIVITY-047 trial for the newly approved OPDUALAG for the unresectable or metastatic melanoma patients. Nivolumab Mechanism of Action:  Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants Recently, FDA approved Opdualag, a fixed-dose combination of nivolumab and relatlimab for patients with previously untreated melanoma that cannot be removed surgically or has spread (metastasized) within the body. The Opdualag FDA approval was based on results from a large Phase II/III clinical trial ( RELATIVITY-047).   The clinical trial results have shown that Opdualag can double the time patients with previously untreated advanced melanoma can live without disease progression compared to Opdivo alone (the current SoC) without any added safety concerns. Further Exploratory analyses by pre-specified subgroups fro